Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema.

Campochiaro PA, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS.

Ophthalmology. 2014 Sep;121(9):1783-9. doi: 10.1016/j.ophtha.2014.03.021.

PMID:
24768239
2.

Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion.

Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG.

Ophthalmology. 2013 Apr;120(4):795-802. doi: 10.1016/j.ophtha.2012.09.032.

PMID:
23260261
3.

Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.

Domalpally A, Ip MS, Ehrlich JS.

Ophthalmology. 2015 Apr;122(4):779-86. doi: 10.1016/j.ophtha.2014.10.028.

4.

Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.

Ip MS, Domalpally A, Sun JK, Ehrlich JS.

Ophthalmology. 2015 Feb;122(2):367-74. doi: 10.1016/j.ophtha.2014.08.048.

5.

Reading speed improvements in retinal vein occlusion after ranibizumab treatment.

Suñer IJ, Bressler NM, Varma R, Lee P, Dolan CM, Ward J, Colman S, Rubio RG.

JAMA Ophthalmol. 2013 Jul;131(7):851-6. doi: 10.1001/jamaophthalmol.2013.114.

PMID:
23699977
6.

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG; BRAVO Investigators..

Ophthalmology. 2010 Jun;117(6):1102-1112.e1. doi: 10.1016/j.ophtha.2010.02.021.

PMID:
20398941
7.

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ; RIDE and RISE Research Group..

Ophthalmology. 2013 Oct;120(10):2013-22. doi: 10.1016/j.ophtha.2013.02.034.

8.

The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema.

Ishibashi T, Li X, Koh A, Lai TY, Lee FL, Lee WK, Ma Z, Ohji M, Tan N, Cha SB, Shamsazar J, Yau CL; REVEAL Study Group..

Ophthalmology. 2015 Jul;122(7):1402-15. doi: 10.1016/j.ophtha.2015.02.006.

PMID:
25983216
9.

Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE.

Bressler NM, Varma R, Suñer IJ, Dolan CM, Ward J, Ehrlich JS, Colman S, Turpcu A; RIDE and RISE Research Groups..

Ophthalmology. 2014 Dec;121(12):2461-72. doi: 10.1016/j.ophtha.2014.07.008.

PMID:
25148789
10.

Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in Retinal Vein Occlusion.

Mir TA, Kherani S, Hafiz G, Scott AW, Zimmer-Galler I, Wenick AS, Solomon S, Han I, Poon D, He L, Shah SM, Brady CJ, Meyerle C, Sodhi A, Linz MO, Sophie R, Campochiaro PA.

Ophthalmology. 2016 Mar;123(3):625-34.e1. doi: 10.1016/j.ophtha.2015.10.030.

PMID:
26712560
11.

Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.

Thach AB, Yau L, Hoang C, Tuomi L.

Ophthalmology. 2014 May;121(5):1059-66. doi: 10.1016/j.ophtha.2013.11.022.

12.

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS; RISE and RIDE Research Group..

Ophthalmology. 2012 Apr;119(4):789-801. doi: 10.1016/j.ophtha.2011.12.039.

PMID:
22330964
13.

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators..

Ophthalmology. 2010 Jun;117(6):1124-1133.e1. doi: 10.1016/j.ophtha.2010.02.022.

PMID:
20381871
14.

Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials.

Bressler NM, Varma R, Mitchell P, Suñer IJ, Dolan C, Ward J, Ferreira A, Ehrlich JS, Turpcu A.

JAMA Ophthalmol. 2016 Feb;134(2):160-6. doi: 10.1001/jamaophthalmol.2015.4636.

PMID:
26584450
15.

Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG.

Ophthalmology. 2011 Oct;118(10):2041-9. doi: 10.1016/j.ophtha.2011.02.038.

PMID:
21715011
16.

Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.

Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH, Seland J, Stene-Johansen I.

Am J Ophthalmol. 2010 Sep;150(3):310-4. doi: 10.1016/j.ajo.2010.03.028.

PMID:
20591399
17.

Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial.

Mitchell P, Bressler N, Tolley K, Gallagher M, Petrillo J, Ferreira A, Wood R, Bandello F; RESTORE Study Group..

JAMA Ophthalmol. 2013 Oct;131(10):1339-47. doi: 10.1001/jamaophthalmol.2013.4592.

PMID:
23974915
18.

Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.

Tan MH, McAllister IL, Gillies ME, Verma N, Banerjee G, Smithies LA, Wong WL, Wong TY.

Am J Ophthalmol. 2014 Jan;157(1):237-247.e1. doi: 10.1016/j.ajo.2013.08.013.

PMID:
24112635
19.

Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.

Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P.

Ophthalmology. 2012 Apr;119(4):802-9. doi: 10.1016/j.ophtha.2011.12.005.

PMID:
22301066
20.

Influence of Glycosylated Hemoglobin on the Efficacy of Ranibizumab for Diabetic Macular Edema: A Post Hoc Analysis of the RIDE/RISE Trials.

Bansal AS, Khurana RN, Wieland MR, Wang PW, Van Everen SA, Tuomi L.

Ophthalmology. 2015 Aug;122(8):1573-9. doi: 10.1016/j.ophtha.2015.04.029.

Items per page

Supplemental Content

Support Center